A fiber-modified mesothelin promoter-based conditionally replicating adenovirus fortreatment of ovarian cancer

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3582-3588

  Tsuruta, Yuko ^a   Pereboeva, Larisa ^a   Breidenbach, Martina ^a,d   Rein, Daniel T ^a,e   Wang, Minghui ^a   Alvarez, Ronald D ^b   Siegal, Gene P ^c   Dent, Paul ^f   Fisher, Paul B ^g   Curiel, David T ^a,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g College of Physicians and Surgeons ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; LUCIFERASE; MESOTHELIN; E1A PROTEIN; MEGAKARYOCYTE POTENTIATING FACTOR; MEMBRANE PROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; VIRUS PARTICLE; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; DRUG SCREENING; GENE VECTOR; GENETICS; METHODOLOGY; MOUSE MUTANT; OVARY TUMOR; POLYMERASE CHAIN REACTION; VIROLOGY;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; FEMALE; GENETIC VECTORS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 50349083397     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5053     Document Type: Article

References (39)

1. Greenlee RT, Hill-Harmon MB, MurrayT,Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001:51:15-36.
2. Stoff-Khalili MA, Dall P, Curiel DT. From gene therapy to virotherapy for ovarian cancer. Minerva Ginecol 2004:56:503-14.
3. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001:3:385-94.
4. Casado E, Gomez-Navarro J, Yamamoto M, et al. Strategies to accomplish targeted expression of trans-genes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001:7:2496-504.
5. Casado E, Nettelbeck DM, Gomez-Navarro J, et al. Transcriptional targeting for ovarian cancer gene therapy. Gynecol Oncol 2001:82:229-37.
6. Barker SD, Coolidge CJ, Kanerva A, et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 2003;5: 300-10
7. Breidenbach M. Rein DT, Everts M, et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther 2005,12:187-93.
8. Gambhir SS, Barrio JR, Herschman HR, Phelps ME Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 1999:26:481 -90.
9. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002:62:4663-70.
10. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT, Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996: 70:6839-46.
11. Rein DT, Breidenbach M, KirbyTO, etal. Afiber-mod-ified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 2005:11: 1327-35.
12. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002:76:8621 -31.
13. Graham F, Prevec L, Manipulation of adenovirus vectors. In: Murray EJ, Walker JM, editors, Methods in molecular biology. Clifton, N.J.: Humana Press: 1991. p. 109-28.
14. Tsuruta Y, Pereboeva L, Glasgow JN, et al. Reovirus σ1 fiber incorporated into adenovirus serotype 5 enhances infectivity via a CAR-independent pathway. Biochem Biophys Res Commun 2005:335:205-14.
15. Maizel JV, Jr., White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12.Virology 1968;36:115-25.
16. Kanerva A, Zinn KR, ChaudhuriTR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003:8:449-58.
17. Kanerva A. Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002,8:275-80.
18. Kim M, Sumerel LA, Belousova N, et al. The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br J Cancer 2003:88:1411 -6.
19. CripeTP, Dunphy EJ, Holub AD. et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001:61: 2953-60.
20. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002:5:695-704.
21. Raki M, Kanerva A, Ristimaki A, et al. Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. GeneTher 2005;12:1198-205
22. Kanerva A, Bauerschmitz G J, Yamamoto M, et al A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. GeneTher 2004:11: 552-9.
23. Zhu ZB, Chen Y, Makhija SK, et al. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int J Oncol 2006;29:1319-29
24. Rocconi RP, Zhu ZB, Stoff-Khalili M, et al Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol Oncol 2007;105:113-21.
25. Ordonez NG. Application of mesothelin immunos-taining in tumor diagnosis. Am J Surg Pathol 2003; 27:1418-28
26. Hassan R, RemaleyAT, Sampson ML, et al Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53.
27. Klerk CP, Overmeer RM, NiersTM, et al. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Bio-techniques 2007;43:7-13, 30.
28. Wessels JT, Busse AC, Mahrt J, Dullin C, Grabbe E, Mueller GA. In vivo imaging in experimental preclinical tumor research-a review. Cytometry A 2007, 71:542-9.
29. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003:16: 192-7.
30. Argani P, lacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 2001.7 3862-8
31. Chowdhury PS,VinerJL. Beers R. Pastan I Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998;95:669 - 74.
32. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro Nat Biotechnol 1999;17:568-72.
33. Zhang Y, Xiang L, Hassan R, Pastan I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors Proc Natl Acad Sci U S A 2007;104:17099-104.
34. Hassan R. Williams-Gould J. Steinberg SM, et al Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts Clin Cancer Res 2006:12 4983-8
35. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers Clin Cancer Res 2007;13:5144-9.
36. Thomas AM, Santarsiero LM, Lutz ER, et al Mesothelin-specific CD8(+) Tcell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306
37. Yokokawa J, Palena C, Arlen P, et al Identification of novel human CTL epitopes and their agonist epitopes of mesothelin Clin Cancer Res 2005;11:6342-51
38. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer a phase I trial of safety and immune activation J Clin Oncol 2001;19:145-56.
39. Sato N, Hassan R, Axworthy DB, et al Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med 2005:46:1201 -9